Conquering Diseases

Aurora: A Study Of An Experimental Drug For Liver Scarring Caused By Nash

Description

Nonalcoholic Steatohepatitis (NASH) is a disease that results when fat accumulates in the liver and eventually causes inflammation and scarring called fibrosis. The purpose of this study is to test whether an experimental drug, CVC, is safe and effective in treating advanced scarring of the liver due to NASH.

Overview

Eligible patients will be randomly assigned to take study drug or placebo. Neither you nor the researchers will know which you are taking. Study visits occur approximately once every 3 months. At these visits researchers will ask you questions about your health, medications you are taking, and if you are having any problems with your health.

What we're hoping for

To find out if the study drug, CVC, is safe and effective for treating patients with NASH and fibrosis.

Additional Information

ClinicalTrials.gov Identifier: NCT03028740

 Principal Investigator

Gyongyi  Szabo, MD

University of Massachusetts Medical School

 Study Contact

Lisa  Hales

774-441-8402

Lisa.Hales@umassmemorial.org

 Location

UMMS University Campus

55 Lake Ave North 

Worcester,MA 01655

508-856-8989